Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H21N5O2 |
Molecular Weight | 351.4023 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCC[C@@H]1CC2=CNC3=C2C=C(NC4=C(C=CC=N4)[N+]([O-])=O)C=C3
InChI
InChIKey=YPFIYPNOWVPAPR-OAHLLOKOSA-N
InChI=1S/C19H21N5O2/c1-23-9-3-4-15(23)10-13-12-21-17-7-6-14(11-16(13)17)22-19-18(24(25)26)5-2-8-20-19/h2,5-8,11-12,15,21H,3-4,9-10H2,1H3,(H,20,22)/t15-/m1/s1
Molecular Formula | C19H21N5O2 |
Molecular Weight | 351.4023 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/8057297Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/9225281 | http://adisinsight.springer.com/drugs/800005784
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8057297
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/9225281 | http://adisinsight.springer.com/drugs/800005784
CP 135807 is a selective 5-HT1D receptor agonist. Preclinical development for migraine was proposed but no development report released. This compound is used for neuroscience research.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1983 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8057297 |
3.1 nM [IC50] | ||
Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8057297 |
33.0 nM [IC50] | ||
Target ID: CHEMBL1898 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9225281 |
1.0 nM [Ki] | ||
Target ID: CHEMBL2095230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9225281 |
2.2 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14758468
3 mg/kg
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15363952
The effect of various compounds on the [35S]GTPgammaS binding mediated by gp5-HT1B receptors – pEC50 = 8.38 (EC50=4.1 nM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:02:15 GMT 2023
by
admin
on
Sat Dec 16 18:02:15 GMT 2023
|
Record UNII |
TE348FQ6DA
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5487088
Created by
admin on Sat Dec 16 18:02:15 GMT 2023 , Edited by admin on Sat Dec 16 18:02:15 GMT 2023
|
PRIMARY | |||
|
DTXSID10164748
Created by
admin on Sat Dec 16 18:02:15 GMT 2023 , Edited by admin on Sat Dec 16 18:02:15 GMT 2023
|
PRIMARY | |||
|
151272-90-1
Created by
admin on Sat Dec 16 18:02:15 GMT 2023 , Edited by admin on Sat Dec 16 18:02:15 GMT 2023
|
PRIMARY | |||
|
CP-135807
Created by
admin on Sat Dec 16 18:02:15 GMT 2023 , Edited by admin on Sat Dec 16 18:02:15 GMT 2023
|
PRIMARY | |||
|
TE348FQ6DA
Created by
admin on Sat Dec 16 18:02:15 GMT 2023 , Edited by admin on Sat Dec 16 18:02:15 GMT 2023
|
PRIMARY |